When a Cure Enters Your Medical Record: CRISPR, Insurance and the UK's Genetic Rulebook

CRISPR therapies are moving from specialist centres into mainstream clinical conversation. For patients, one question arrives almost as soon as the science does: not only will it work, but what will it do to my insurance? The short answer is that the answer depends less on the word CRISPR than on what is written in the medical record and what kind of test produced it.

The rule as it stands

The UK does not ban genetic discrimination by statute. Instead, it relies on a voluntary agreement between the Government and the Association of British Insurers: the Code on Genetic Testing and Insurance. The Code is often described as a moratorium. It says insurers will not require or use predictive genetic test results, with one exception: Huntington's disease for life cover above £500,000.

The Code is important, but it is narrow. It does not stop insurers asking about symptoms, diagnoses, family history or treatment. It does not make genetic information a protected characteristic in its own right. And it is not enforced by a single regulator. Complaints can go to the Financial Ombudsman Service, but the Code is not a statute that automatically voids a policy.

Why a somatic edit is not a predictive test

Somatic CRISPR changes cells in a patient's body. It does not change eggs or sperm, and it is not inherited. It is treatment, not forecast. The Code's trigger is a predictive genetic test: a test used to estimate future risk in someone who does not yet have symptoms. A somatic edit does not create an inherited risk, and it does not turn a patient into a carrier. The act of editing is therefore unlikely to fall within the Code's exception.

But the data around it might. Trials often sequence tumour or blood samples, and some of that sequencing can produce predictive findings about other conditions. If an insurer requested or used those results, the Code should apply. If the same sequencing reveals a diagnosis, that is clinical information, not a predictive test. The distinction matters, and patients should not assume that every sequenced letter is covered by the same rule.

The pre-existing condition puzzle

Insurance underwriting is not a single national rule. 'Pre-existing condition' is policy wording, not a statutory term. For a new policy, an insurer asks about medical history. If a patient has had sickle cell disease and later receives a CRISPR therapy, the diagnosis and the treatment are material facts. A successful edit may change prognosis. It does not rewrite history.

Insurers may ask about current health, treatment and complications. The Code does not require them to ignore a diagnosis because it has been treated. This is the gap patients notice: a cure can feel like a clean slate, but underwriting works from records. The practical question is not 'Have you had CRISPR?' but 'What diagnosis, test result and treatment will appear in my file, and how will this insurer treat them?'

What the Code does not cover

Three gaps stand out. First, the Code covers predictive genetic tests, not all genetic data. Somatic sequencing may be diagnostic. Second, it does not cover product design: critical-illness definitions, waiting periods and exclusions are matters of contract. Third, it does not create a right to erasure, nor a duty to explain insurance in trial consent. A trial may not mention insurance at all. Patients should not assume a consent form has resolved the question.

Questions before signing

Ask whether the genetic test is predictive or diagnostic. Ask whether the trial will sequence genes beyond the target. Ask which results will go into the NHS record and whether additional findings can be declined. Ask what the GP record will say after treatment. Ask whether the sponsor will share data with insurers. Ask what happens if you apply for life cover in five years. Get answers in writing.

If an insurer asks about genetic tests, answer truthfully and seek specialist advice; do not guess. If a decision appears to use a predictive result contrary to the Code, request the underwriting rationale and consider the Financial Ombudsman Service.

A policy question for 2026

The deeper issue is whether a voluntary Code is enough as one-off therapies become routine. Parliament could legislate. Regulators could issue guidance. Trial sponsors could add a standard insurance paragraph to patient information. Until then, patients need a map, not reassurance. A CRISPR cure may be transformative. It is not an eraser.